Keith G Tolman

Summary

Affiliation: University of Utah
Country: USA

Publications

  1. pmc Treatment of non-alcoholic fatty liver disease
    Keith G Tolman
    Division of Gastroenterology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA
    Ther Clin Risk Manag 3:1153-63. 2007
  2. ncbi request reprint Hepatotoxicity of the thiazolidinediones
    Keith G Tolman
    Division of Gastroenterology, Department of Internal Medicine, University of Utah School of Medicine, 30 N 1900 E RM 4R118 SOM Salt Lake City, UT 84132, USA
    Clin Liver Dis 7:369-79, vi. 2003
  3. ncbi request reprint Narrative review: hepatobiliary disease in type 2 diabetes mellitus
    Keith G Tolman
    University of Utah and University Hospitals and Clinics, Salt Lake City, Utah 84132, USA
    Ann Intern Med 141:946-56. 2004
  4. ncbi request reprint Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteers
    Keith G Tolman
    University of Utah School of Medicine, Salt Lake City, Utah, USA
    Clin Drug Investig 26:21-8. 2006
  5. ncbi request reprint Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease
    Keith G Tolman
    Division of Gastroenterology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA
    Diabetes Care 30:734-43. 2007
  6. doi request reprint Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US
    Keith G Tolman
    University of Utah, Salt Lake City, Utah, USA
    Drug Saf 32:787-800. 2009
  7. ncbi request reprint The liver and lovastatin
    Keith G Tolman
    University of Utah School of Medicine, Salt Lake City, Utah 84132, USA
    Am J Cardiol 89:1374-80. 2002
  8. ncbi request reprint Reply to Dr. Dujovne's editorial
    Keith G Tolman
    Am J Cardiol 89:1452. 2002
  9. ncbi request reprint The therapeutic use of acetaminophen in patients with liver disease
    Gordon D Benson
    Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, 401 Haddon Avenue, Camden, NJ 08103, USA
    Am J Ther 12:133-41. 2005

Detail Information

Publications9

  1. pmc Treatment of non-alcoholic fatty liver disease
    Keith G Tolman
    Division of Gastroenterology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA
    Ther Clin Risk Manag 3:1153-63. 2007
    ..There are fewer, but promising data, with statins which have been shown to be hepatoprotective in other liver diseases. The initial enthusiasm for ursodeoxycholic acid has not been supported by histologic studies...
  2. ncbi request reprint Hepatotoxicity of the thiazolidinediones
    Keith G Tolman
    Division of Gastroenterology, Department of Internal Medicine, University of Utah School of Medicine, 30 N 1900 E RM 4R118 SOM Salt Lake City, UT 84132, USA
    Clin Liver Dis 7:369-79, vi. 2003
    ..All of the thiazolidinediones cause ALT elevations; however, ALT monitoring for hepatotoxicity does not appear to prevent serious liver disease nor reduce patient risk...
  3. ncbi request reprint Narrative review: hepatobiliary disease in type 2 diabetes mellitus
    Keith G Tolman
    University of Utah and University Hospitals and Clinics, Salt Lake City, Utah 84132, USA
    Ann Intern Med 141:946-56. 2004
    ....
  4. ncbi request reprint Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteers
    Keith G Tolman
    University of Utah School of Medicine, Salt Lake City, Utah, USA
    Clin Drug Investig 26:21-8. 2006
    ....
  5. ncbi request reprint Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease
    Keith G Tolman
    Division of Gastroenterology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA
    Diabetes Care 30:734-43. 2007
  6. doi request reprint Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US
    Keith G Tolman
    University of Utah, Salt Lake City, Utah, USA
    Drug Saf 32:787-800. 2009
    ..We conducted a randomized, long-term, double-blind, hepatic safety study at 171 centres in the US in which 2097 patients with type 2 diabetes received either pioglitazone or glibenclamide (glyburide)...
  7. ncbi request reprint The liver and lovastatin
    Keith G Tolman
    University of Utah School of Medicine, Salt Lake City, Utah 84132, USA
    Am J Cardiol 89:1374-80. 2002
    ..In fact, it may increase patient risk because of needless discontinuation of cholesterol-lowering therapy for false-positive results in patients who are benefiting from treatment...
  8. ncbi request reprint Reply to Dr. Dujovne's editorial
    Keith G Tolman
    Am J Cardiol 89:1452. 2002
  9. ncbi request reprint The therapeutic use of acetaminophen in patients with liver disease
    Gordon D Benson
    Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, 401 Haddon Avenue, Camden, NJ 08103, USA
    Am J Ther 12:133-41. 2005
    ....